Nabi Nabi-HB
Executive Summary
Hepatitis B immune globulin approved by FDA March 24 for intramuscular use. Nabi-HB is indicated for use following sexual exposure to hepatitis B surface antigen positive persons, household exposure to persons with acute hepatitis B virus infection, acute exposure to blood containing HBsAg and perinatal exposure for infants born to HBsAg-positive mothers. Nabi plans to market Nabi-HB immediately
You may also be interested in...
Hemopure to BPAC
Biopure's oxygen therapeutic Hemopure (hemoglobin glutamer - 250 [bovine]) for out-of-hospital treatment of hemorrhagic shock due to traumatic injury will be the subject of a closed-door review by FDA's Blood Products advisory committee July 14, the company said. BPAC will also hear FDA's review of Nabi Biopharmaceuticals' Hepatitis B Immunoglobulin Intravenous for prevention of recurrent Hepatitis B Virus Disease after orthotopic liver transplantation July 13. Nabi-HB is already approved for intramuscular use (1"The Pink Sheet" March 29, 1999, In Brief)...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011